NewsRoom Articles - Page 45 of 154 - PsychedelicNewsWire (PNW)

FridayNov 04, 2022 12:58 pm

NIH Funds Research to Investigate Psilocybin’s Effectiveness in Helping Smokers Quit

The National Institutes of Health has awarded a grant to researchers at Johns Hopkins University to find out whether psychedelics can help smokers quit smoking. This is the first time in decades that a federal grant has been awarded to carry out research on a psychedelic as a potential treatment. We have seen interest in psychedelics grow significantly these last few years, especially as more studies find that these drugs may be useful in the treatment of a range of mental health disorders, including post-traumatic stress disorder, depression and addiction. For instance, research published a few months ago found that…

FridayNov 04, 2022 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease

Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company, fuses traditional therapeutics with psychedelic medicine to treat numerous underserved conditions, including fibromyalgia, post-traumatic stress disorder, and Alzheimer’s disease. Through a joint partnership agreement with Columbia University, researchers are currently…

ThursdayNov 03, 2022 2:01 pm

DiPT: The Psychedelic That Causes Auditory Hallucinations

DiPT (N,N-diisopropyltryptamine) is a psychedelic drug of the tryptamine family that induces auditory hallucinations. This means that unlike other hallucinogens which cause visual hallucinations by affecting an individual’s visual sense, DiPT causes hallucinations where an individual can hear sounds. DiPT was first created and experimented with by Alexander Shulgin in 1980. It is chemically related to DMT, which is another hallucinogen of the tryptamine family. How does the drug work? Despite its creation decades ago, not much is known about how DiPT works. Zeus Tipado, a psychedelic neuroscience researcher, states that researchers know that the drug affects the same region…

WednesdayNov 02, 2022 1:33 pm

Research Finds That Psychedelics Users Are More Connected to Nature

We are currently in the midst of a major psychedelics renaissance. Decades after the United States outlawed the production, purchase and consumption of psychedelic drugs such as LSD and MDMA, states are loosening their psychedelic policies and allowing for more research into these mind-altering drugs. Furthermore, a growing number of people are using psychedelics for recreational and medical purposes, with a recent study finding that around 28% of Americans have used LSD, MDMA, ketamine, DMT, mescaline, salvia or psilocybin. A new study has now found that individuals who consume hallucinogenic drugs such as psilocybin tend to be more connected to…

TuesdayNov 01, 2022 12:19 pm

US DEA Facing Fresh Lawsuits After Denying Psilocybin Waiver, Rescheduling Request

For more than a year, a palliative care specialist has been fighting to be granted permission by the U.S. Drug Enforcement Administration (DEA) to administer psilocybin to his patients. Dr. Sunil Aggarwal had requested a federal waiver under the Right to Try statute, which would have allowed him to administer the psychedelic to his patients with terminal illnesses. Aggarwal explained that Right to Try laws clearly stipulate that severely ill individuals qualified for investigational drugs, including psychedelics. However, the DEA rejected the request as well as a petition the doctor filed to reschedule psilocybin. In its argument, the federal agency…

MondayOct 31, 2022 12:05 pm

Compass Pathways Announces First-Ever Phase 3 Human Psilocybin Trial

Psychedelics have long been heralded for their numerous benefits, with recent studies showing that these substances may be useful in the treatment of various mental health conditions. These benefits have increased interest in these substances, with Compass Pathways PLC (NASDAQ: CMPS) recently announcing that the company plans to begin a phase 3 human trial, which will investigate the effectiveness psilocybin in treating depression this year. This will be the first human trial of this magnitude involving psychedelic therapy globally. Compass Pathways is a mental healthcare company focused on transforming patient experiences in mental healthcare. The company has developed a psilocybin…

FridayOct 28, 2022 10:18 am

Microscopy Provides Insights on Psychedelics Action Inside Neuropathways

Psychedelics have been used for centuries by different cultures, with their popularity in the 1960s prompting research into their benefits. Until now, however, researchers are yet to fully understand how these substances actually work in the brain. Associate professor Alex Kwan of the Meinig School of Biomedical Engineering is mapping the neural response of these hallucinogens in the brain through the use of optical microscopy. This may, in the future, lead to the development of treatments for cluster headaches and substance-use disorders as well as fast-acting antidepressants. Kwan stated that while researchers knew how psychedelics worked at the structural level,…

ThursdayOct 27, 2022 12:30 pm

Venture Studio Establishes Equity Crowdfunding Drive to Boost Psychedelics Therapies

Nucleus will soon launch a crowdfunding campaign whose goal is to expand the interactions individuals have with the psychedelics industry. The objective of the psychedelics venture studio, which operates as an Iter Investments subsidiary, is to drive psychedelic-assisted therapy forward in the middle of the current global mental health crisis. Iter Investments’ active portfolio is comprised of more than 15 companies with special access to new investments, including clinics such as Wesana Health and Awakn Life Sciences; active psychedelic ingredient suppliers, including Psygen; drug research and development companies such as Beckley Psytech, Psilera, Clairvoyant, Apex Labs, Reset Pharma, Wesana, Freedom…

WednesdayOct 26, 2022 3:09 pm

As Competition Stiffens, Patent Wars Intensify in Psychedelics Space

The medicinal psychedelics space is continuing to grow as interest from the public increases and more research on these substances is conducted. Additionally, issued psychedelic patents portfolios are getting larger, with challenges to these patents being filed with the U.S. Patent and Trademark Office. These patents may shape the trajectory of this burgeoning space, especially in the short term. The need for psychedelic compounds to be treated as common pharmaceutical medications is one of the primary reasons why some patents in this infant industry have been challenged. In the past, patents helped encourage innovation in biopharmaceutical companies by protecting the…

TuesdayOct 25, 2022 12:39 pm

Survey Finds No Link Between Psychedelics Use, Cancer Risk

New research has found that the use of psychedelic substances is not linked to the lifetime development of cancer. The investigators’ objective was focused on determining whether there was any truth to research from the 1960s that associated the use of psychedelics to a heightened risk of developing cancer. The research in question was conducted in 1967, with those involved reporting that the use of LSD caused chromosomal damage in white blood cells. Subsequent studies also suggested that exposure to LSD could have carcinogenic potential. For their study, the researchers focused on expanding on a 2021 study that explored the…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000